Innovent Biologics advances their PD-1 × IL-2 antibody fusion IBI363 into registrational studies after demonstrating Phase I/II efficacy across three cold tumor types. This bispecific approach positions these fusions as potential challengers to Keytruda in immuno-oncology, exploiting synergistic checkpoint and cytokine pathways to activate immune responses in difficult-to-treat cancers.